Prestige Biologics hires former Lonza official as new director

Prestige Biologics, a biopharmaceutical contract development, engineering, and manufacturing organization (CDEMO), said it has appointed Fionn Huang, formerly of the global CDMO Lonza Group, as the new director for its international business development.

Ms. Huang brings more than 15 years of experience in the global CDMO industry, overseeing processes, business development, and sales management. After earning a bachelor of science in biomedical sciences from the National University of Singapore (NUS) and an executive MBA (EMBA) from the Quantic School of Business and Technology in the United States, Huang has worked for Lonza, Merck, and Thermo Fisher.

Huang spent 10 years in production, GMP certification, marketing, and sales, starting in quality assurance at the U.S. and Singapore offices of Lonza, the No. 1 global CDMO. She also served as a CDMO sales director for Asia-Pacific customers, including China, at Merck, a global pharmaceutical giant, and as a sales leader at Thermo Fisher Scientific, a U.S. biopharmaceutical company, where she performed automation and GMP-related tasks for biopharmaceutical production facilities.

Prestige Biologics expects Ms. Huang's appointment to accelerate CDMO sales in the U.S. and China. Huang is fluent in both English and Chinese, and the company said her experience and network in the China and Singapore offices of global CDMOs will be utilized to target the Chinese market.

It added that she would focus on strategies to help Prestige Biologics win orders from Chinese CDMOs, including WuXi Biologics, which the U.S. restricts.

"The appointment of Director Fionn Huang, who is a China expert, is a proactive and proactive response to the U.S. biosecurity law issue, and we are gradually preparing for the full operation of the factory by securing additional global sales experts and working staff," a Prestige Biologics official said.

Director Huang said, "The extensive network and experience in biopharmaceutical production that I have accumulated over the years in global pharmaceutical companies will combine with K-Bio to create various business opportunities."